216 related articles for article (PubMed ID: 22198310)
1. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy.
Rezvani K; Yong AS; Mielke S; Savani BN; Jafarpour B; Eniafe R; Le RQ; Musse L; Boss C; Childs R; John Barrett A
Cancer Immunol Immunother; 2012 Jul; 61(7):1125-36. PubMed ID: 22198310
[TBL] [Abstract][Full Text] [Related]
2. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Savani BN; Musse L; Superata J; Jafarpour B; Boss C; Barrett AJ
Blood; 2008 Jan; 111(1):236-42. PubMed ID: 17875804
[TBL] [Abstract][Full Text] [Related]
3. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.
Yong AS; Rezvani K; Savani BN; Eniafe R; Mielke S; Goldman JM; Barrett AJ
Blood; 2007 Jul; 110(2):770-5. PubMed ID: 17412886
[TBL] [Abstract][Full Text] [Related]
4. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Jafarpour B; Savani BN; Le RQ; Eniafe R; Musse L; Boss C; Kurlander R; Barrett AJ
Haematologica; 2011 Mar; 96(3):432-40. PubMed ID: 21134985
[TBL] [Abstract][Full Text] [Related]
5. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
Qazilbash MH; Wieder E; Thall PF; Wang X; Rios R; Lu S; Kanodia S; Ruisaard KE; Giralt SA; Estey EH; Cortes J; Komanduri KV; Clise-Dwyer K; Alatrash G; Ma Q; Champlin RE; Molldrem JJ
Leukemia; 2017 Mar; 31(3):697-704. PubMed ID: 27654852
[TBL] [Abstract][Full Text] [Related]
6. PR1 vaccination in myeloid malignancies.
Rezvani K
Expert Rev Vaccines; 2008 Sep; 7(7):867-75. PubMed ID: 18767937
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
Maslak PG; Dao T; Krug LM; Chanel S; Korontsvit T; Zakhaleva V; Zhang R; Wolchok JD; Yuan J; Pinilla-Ibarz J; Berman E; Weiss M; Jurcic J; Frattini MG; Scheinberg DA
Blood; 2010 Jul; 116(2):171-9. PubMed ID: 20400682
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
Rezvani K; Yong AS; Savani BN; Mielke S; Keyvanfar K; Gostick E; Price DA; Douek DC; Barrett AJ
Blood; 2007 Sep; 110(6):1924-32. PubMed ID: 17505014
[TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.
Ochsenreither S; Fusi A; Geikowski A; Stather D; Busse A; Stroux A; Letsch A; Keilholz U
Cancer Immunol Immunother; 2012 Mar; 61(3):313-22. PubMed ID: 21898091
[TBL] [Abstract][Full Text] [Related]
10. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
Yong AS; Keyvanfar K; Eniafe R; Savani BN; Rezvani K; Sloand EM; Goldman JM; Barrett AJ
Leukemia; 2008 Sep; 22(9):1721-7. PubMed ID: 18548092
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
[TBL] [Abstract][Full Text] [Related]
13. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
Rezvani K; Grube M; Brenchley JM; Sconocchia G; Fujiwara H; Price DA; Gostick E; Yamada K; Melenhorst J; Childs R; Hensel N; Douek DC; Barrett AJ
Blood; 2003 Oct; 102(8):2892-900. PubMed ID: 12829610
[TBL] [Abstract][Full Text] [Related]
14. Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.
Busse A; Letsch A; Scheibenbogen C; Nonnenmacher A; Ochsenreither S; Thiel E; Keilholz U
J Transl Med; 2010 Jan; 8():5. PubMed ID: 20092642
[TBL] [Abstract][Full Text] [Related]
15. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
16. Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.
Lacey SF; La Rosa C; Kaltcheva T; Srivastava T; Seidel A; Zhou W; Rawal R; Hagen K; Krishnan A; Longmate J; Andersson HA; St John L; Bhatia R; Pullarkat V; Forman SJ; Cooper LJ; Molldrem J; Diamond DJ
Blood; 2011 Aug; 118(8):2159-69. PubMed ID: 21719601
[TBL] [Abstract][Full Text] [Related]
17. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
[TBL] [Abstract][Full Text] [Related]
18. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
Greiner J; Döhner H; Schmitt M
Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
[TBL] [Abstract][Full Text] [Related]
19. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
20. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
Nakae Y; Oka Y; Fujiki F; Morimoto S; Kamiya T; Takashima S; Nakata J; Nishida S; Nakajima H; Hosen N; Tsuboi A; Kyo T; Oji Y; Mizuguchi K; Kumanogoh A; Sugiyama H
Cancer Immunol Immunother; 2015 Jul; 64(7):791-804. PubMed ID: 25835542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
